The Current Status and Prospects of Antibody Engineering for Therapeutic Use: Focus on Glycoengineering Technology

• Published in: Journal of pharmaceutical sciences Vol. 104; no. 3; pp. 930 - 941
• Main Authors: Niwa, Rinpei, Satoh, Mitsuo
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.03.2015; Elsevier Limited
• Subjects: Antibodies, Bispecific - biosynthesis; Antibodies, Bispecific - chemistry; Antibodies, Bispecific - therapeutic use; Antibodies, Monoclonal - biosynthesis; Antibodies, Monoclonal - chemistry; Antibodies, Monoclonal - therapeutic use; Antibody Specificity; biotechnology; cancer; conjugation; Glycosylation; Immunoconjugates - chemistry; Immunoconjugates - metabolism; Immunoconjugates - therapeutic use; immunology; immunotherapy; Immunotherapy - methods; Protein Conformation; Protein Engineering; Protein Processing, Post-Translational; Structure-Activity Relationship; targeted drug delivery; Technology, Pharmaceutical - methods; Therapeutic antibody; biotechnology; Therapeutic antibody; immunotherapy; glycosylation; targeted drug delivery; cancer; immunology; conjugation
• ISSN: 0022-3549; 1520-6017
• DOI: 10.1002/jps.24316

Monoclonal antibodies have demonstrated enormous potential as new classes of drugs that confer great benefits to patients, and more than 40 therapeutic antibodies have already been approved for clinical use. In particular, the past 5years might be recognized as the period guiding the new era for “engineered antibodies,” with the successful approval of numerous antibody–drug conjugates, bispecific antibodies, and glyco-engineered antibodies for clinical applications. In this review, we summarize the development of antibody engineering technologies that are proving their concepts in the clinic, mainly focusing on the latest trends in defucosylated antibody technologies.